内容摘要：It’s rare for vaccinated people to get measles, but officials say that may account for up to 10% of cases here, though they’re milder.

It’s rare for vaccinated people to get measles, but officials say that may account for up to 10% of cases here, though they’re milder.

“Unfortunately, this extra spending and staff has not improved our nation’s health as a country,”in The New York Post. “Instead, it has only created more waste, administrative bloat and duplication.”

Yet some health experts say the eliminated programs are not duplicative, and erasing them will leave Americans in the dark.“If the U.S. is interested in making itself healthier again, how is it going to know, if it cancels the programs that helps us understand these diseases?” said Graham Mooney, a Johns Hopkins University public health historian.The core of the nation’s health surveillance is done by the CDC’s

. Relying on birth and death certificates, it generates information on birth rates, death trends and life expectancy. It also operates longstanding health surveys that provide basic data on obesity, asthma and other health issues.The center has been barely touched in layoffs, and seems intact under current budget plans.

But many other efforts were targeted by the cuts, the AP found. Some examples:

, which surveys women across the country, lost its entire staff — about 20 people.Hoeg — along with Makary and Prasad — spent much of the COVID-19 pandemic criticizing the FDA’s handling of booster shots, particularly in children and young adults. All three were co-authors of a 2022 paper stating that requiring booster shots in young people would cause more harm than benefit.

Novavax isn’t the only vaccine manufacturer already affected by changing attitudes at FDA. Earlier this month, Moderna pushed back the target date for its new COVID-and-flu combination vaccine to next year after the FDA requested additional effectiveness data.As the FDA’s top official overseeing vaccines, Prasad is now in position to reverse what he recently called “a number of missteps” in how the FDA assessed the benefits and risks of COVID-19 boosters.

He questioned how much benefit yearly vaccinations continue to offer. In a podcast shortly before assuming his FDA job, Prasad suggested companies could study about 20,000 older adults in August or September to show if an updated vaccine prevented COVID-related hospitalizations.There is “legitimate debate about who should be boosted, how frequently they should be boosted and the value of boosting low-risk individuals,” said Hopkins’ Adalja. But he stressed that CDC’s Advisory Committee on Immunization Practices has the proper expertise to be making those decisions.